Medical/Pharmaceuticals News & Press Release Distribution

ArisGlobal Accelerates Growth and AI Adoption Following Strong 2025 Performance

More than 100 new and expanded LifeSphere customers, 34 global go-lives, and rapid enterprise adoption of NavaX signal strong momentum BOSTON, Jan. 14, 2026 /PRNewswire/ -- ArisGloba

2026-01-13 23:54 1716

Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral sclerosis (ALS). The initial dosing occurred at Second ...

2026-01-13 20:30 2865

Leo International Group Relocates Global Headquarters to Singapore Ahead of Its Centennial

Embodying a New Model of Inter-generational Enterprise Anchored in Healthcare, Finance and Education SINGAPORE, Jan. 13, 2026 /PRNewswire/ -- As Leo International Group approaches its centennial year in 2026, the Group is not merely commemorating a hundre...

2026-01-13 20:20 1623

Leo International Group Relocates Global Headquarters to Singapore Ahead of Its Centennial

Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ

SHANGHAI, Jan. 13, 2026 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from its Phase I/IIa study of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy, in patients with advanced gastric ...

2026-01-13 16:26 4098

ER-VIPE Simulation Game Builds Medical Students' Soft Skillsfor Real-World Emergency Care

BANGKOK, Jan. 13, 2026 /PRNewswire/ -- Chulalongkorn University 's Faculty of Medicine has developed ER-VIPE , a virtual emergency-room simulation platform designed to strengthen teamwork,...

2026-01-13 15:37 6180

ER-VIPE Simulation Game Builds Medical Students' Soft Skillsfor Real-World Emergency Care

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...

2026-01-13 11:07 3270

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...

2026-01-13 11:07 4843

Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...

2026-01-13 08:54 2826

Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...

2026-01-13 08:54 1658

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

* AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx * AbbVie will commit $100 billion in U.S. research and development (R&D) and capital investments, including manufacturing, over the nex...

2026-01-13 07:30 1387

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research

FREMONT, Calif., Jan. 13, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay. This innovative solution enables ...

2026-01-13 06:27 4524

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research

diaTribe Convenes International Consensus to Guide Diabetes Technology Use During Pregnancy

Expert recommendations provide crucial guidance to leverage CGM and AID during pregnancy. SAN FRANCISCO, Jan. 13, 2026 /PRNewswire/ -- The diaTribe Foundation announces the publication of the first international consensus statement on the use of continuous glucose monitoring (CGM) and automated ...

2026-01-13 01:22 3056

Field Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

CARDIFF-BY-THE-SEA, Calif., Jan. 12, 2026 /PRNewswire/ -- Field Medical Inc., a clinical-stage medical technology company advancing a versatile, next-generation pulsed field ablation (PFA) platform designed to support both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation, today ...

2026-01-12 23:03 3599

Field Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

Suvoda sets new standard for streamlined patient and site experience in clinical trials

CONSHOHOCKEN, Pa., Jan. 12, 2026 /PRNewswire/ -- Suvoda, a clinical trial technology company, took decisive steps in 2025 toward a more connected and streamlined clinical trial experience for both patients and sites. The company's merger with Greenphire marked a pivotal moment in that journey, s...

2026-01-12 23:00 4631

Basecamp Research launches world-first AI models for programmable gene insertion

* The breakthrough tackles a longstanding challenge in genetic medicine with the goal of developing a new generation of curative cell and gene therapies. * Developed in collaboration with NVIDIA by training the largest evolutionary AI models on a new, globally collected dataset, accelerated by...

2026-01-12 23:00 4168

Datasea Announces Major Acoustic Technology Advancements in Brain-Computer Interface Applications

Acoustic-Driven Technologies Poised to Support Embodied Intelligence and Health Robotics Applications in a Multi-Billion-Dollar Brain–Computer Interface Market BEIJING, Jan. 12, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in aco...

2026-01-12 22:30 1538

Deepson Bio Receives Presidential Award at 2025 Korea Invention Patent Exhibition

Award highlights promise of ultrasound-based innovation in addressing unmet needs in dementia treatment SEOUL, South Korea, Jan. 12, 2026 /PRNewswire/ -- Deepson Bio Co., Ltd., a medical technology company focused on ultrasound-based approaches to dementia treatment, was honored with the Preside...

2026-01-12 22:00 786

Deepson Bio Receives Presidential Award at 2025 Korea Invention Patent Exhibition

LumiMind Wins SPEED AWARD at CES 2026 for Innovative Non-Invasive Sleep Technology With Real-Time EEG

LAS VEGAS, Jan. 12, 2026 /PRNewswire/ -- LumiMind, a next-generation neurotechnology company advancing non-invasive brain health solutions, today announced that it has won theSPEED AWARD at CES 2026 for its breakthrough consumer sleep technology,LumiSleep.

2026-01-12 22:00 775

LumiMind Wins SPEED AWARD at CES 2026 for Innovative Non-Invasive Sleep Technology With Real-Time EEG

Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease

CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of first patient first dose in BETHESDA: a Phase IIa clinical trial of ISM5411 (NCT07265570

2026-01-12 21:30 1498

WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a state-of-the-art digital twin platform designed to transform bioprocess development and manufactur...

2026-01-12 21:09 3608